Neuroinflammation: friend and foe for ischemic stroke.
Jayaraj RL, Azimullah S, Beiram R, Jalal FY, Rosenberg GA. · 2019
Read Neuroinflammation: friend and foe for ischemic stroke. by Jayaraj RL, Azimullah S, Beiram R, Jalal FY, Rosenberg GA. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6617684.txt.
Introduction
Jayaraj and co-authors review the double role of inflammation after ischemic stroke. Their article appears in the Journal of Neuroinflammation. Stroke ranks third among causes of death and disability worldwide. Most strokes are ischemic, from a blocked artery. The damage does not end when blood flow stops.
After the first injury, immune signals wake resident brain cells. Neutrophils, monocytes, and T cells then enter the damaged zone. Their attack can kill more cells and widen the injury. Yet the same response later supports repair and recovery. Timing decides which face dominates. The review covers oxidative stress, excitotoxicity, and matrix enzymes as amplifiers. The authors argue that time-aware therapy could protect the brain better.
Catalog record
| CREATOR | Jayaraj RL, Azimullah S, Beiram R, Jalal FY, Rosenberg GA. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 142 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Neuroinflammation: friend and foe for ischemic stroke By Richard L Jayaraj, Sheikh Azimullah, Rami Beiram, Fakhreya Y Jalal, Gary A Rosenberg Published in: Journal of Neuroinflammation DOI: 10.1186/s12974-019-1516-2 ABSTRACT Abstract Stroke, the third leading cause of death and disability worldwide, is undergoing a change in perspective with the emergence of new ideas on neurodegeneration. The concept that stroke is a disorder solely of blood vessels has been expanded to include the effects of a detrimental interaction between glia, neurons, vascular cells, and matrix components, which is collectively referred to as the neurovascular unit. Following the acute stroke, the majority of which are ischemic, there is secondary neuroinflammation that both promotes further injury, resulting in cell death, but conversely plays a beneficial role, by promoting recovery. The proinflammatory signals from immune mediators rapidly activate resident cells and influence infiltration of a wide range of inflammatory cells (neutrophils, monocytes/macrophages, different subtypes of T cells, and other inflammatory cells) into the ischemic region exacerbating brain damage. In this review, we discuss how neuroinflammation has both beneficial as well as detrimental roles and recent therapeutic strategies to combat pathological responses. Here, we also focus on time-dependent entry of immune cells to the ischemic area and the impact of other pathological mediators, including oxidative stress, excitotoxicity, matrix metalloproteinases (MMPs), high-mobility group box 1 (HMGB1), arachidonic acid metabolites, mitogen-activated protein kinase (MAPK), and post-translational modifications that could potentially perpetuate ischemic brain damage after the acute injury. Understanding the time-dependent role of inflammatory factors could help in developing new diagnostic, prognostic, and therapeutic neuroprotective strategies for post-stroke inflammation. Keywords: Stroke, Neuroinflammation, Ischemia, Blood-brain barrier INTRODUCTION Although stroke is the third leading cause of death after heart disease and cancer, it leads to permanent disabilities in 80% of survivors [1, 2]. Stroke can be classified into ischemic or hemorrhagic, in which 85% of strokes are ischemic [3]. Worldwide, cerebrovascular disease and in particular stroke causes a large percentage (47–67%) of disability-adjusted life years and death [4]. Ischemic stroke is characterized by arterial occlusion due to embolus or thrombus [5]. The functional and metabolic irregularities that occur during ischemic stroke largely depend on the artery that is occluded, which in turn determines the size of the ischemic area in the brain [6]. In 2014, a review by Mehndiratta et al. reported that there is an increase in incidence of ischemic stroke subtypes in Asian countries, since Arab countries have identical epidemiological characteristics to other Asian countries, that would suggest an increase in ischemic stroke in Arab countries as well [7]. Moreover, reports from a population-based screening program indicate that there is a very high risk for cardiovascular disease, especially diabetes and obesity in the United Arab Emirates [8, 9]. These reports indicate that there will be a substantial increase in stroke burden, which results in substantial economic and societal costs [10]. Thus, understanding molecular neuroinflammatory mechanisms could significantly potentiate therapeutic development. While the changes due to loss of glucose and oxygen, including the triggering of a series of oxidative, biochemical, and hormonal reactions culminating in microvasculature injury and blood-brain barrier (BBB) disruption, are well established, less well understood are secondary inflammatory cells and their mechanisms that in turn initiate excitotoxicity, reactive oxygen species (ROS), and nitric oxidative species (NOS), and these events will be the focus of the following discussion [11]. IMPACT OF INFLAMMATORY CELLS ON STROKE Various studies demonstrate that apart from neurons, other cells are involved in the pathogenesis of ischemia. Moreover, neuronal, glial, and vascular elements together form a functional “neurovascular unit.” Following ischemic stroke, microglia and astrocytes are activated within hours, leading to the production of cytokines and chemokines [6] and resulting in infiltration of leukocytes [12, 13]. Microglia Microglia, the resident innate immune cells of the brain that represent 5–20 % of the glial population, are activated after ischemic stroke resulting in morphological and phenotypical changes [14]. Activated microglia act similarly to macrophages during systemic inflammation, and they have the ability to phagocytose (clearing foreign organisms and cellular debris) and produce cytokines and MMPs that can compromise BBB function [13]. Whereas, quiescent resting microglia are in a ramified state defined by a small cell soma with wide branches projecting out [15, 16]. However, following ischemia, microglia cells are activated but the precise mechanisms are still not clear. Transient focal cerebral ischemia caused by 15 min of transient middle cerebral artery occlusion (tMCAO) in spontaneously hypertensive stroke-prone rat (SHRSP) leads to activation of microglia in the cerebral cortex of the ischemic hemisphere, and the severity of injury may be reflected in the state of microglial activation [17]. Microglia-mediated neurotoxicity is augmented by the production of ROS via NADPH oxidase [18], cytokines [6], and MMPs [13, 19]. Sun et al. demonstrated that inhibition of microglial activation by 2% isoflurane in transient focal cerebral ischemia rats (reperfusion after 90 min of ischemia) reduced infarct volume, attenuated apoptosis, and significantly decreased microglial activation in ischemic penumbra [20]. Microglial activation also causes secondary death in the penumbra region [21]. Various studies have reported that CD14 receptors (activated by iNOS) followed by toll-like receptor 4 (TLR4) are expressed in activated microglia in infarct brain region, and hence, this could be a possible microglial activation mechanism [22, 23]. In 2017, McDonough et al. demonstrated that sequential exposure of wild-type and TLR4−/− microglia to hypoxia/hyperglycemia (H/H) and normoxia/normoglycemia (N/N) resulted in enhanced expression of type-1 interferon-stimulated genes (ISG) in H/H-N/N wild-type microglia and not in TLR4−/− microglia. Type-1 interferons such as interferon-α and interferon-β activate interferon-α/β receptor (IFNAR) complex and microglial type-1 interferon-stimulated gene expression and were dependent on IFNAR1. During H/H conditions, interferon-β induces secretion of ISG chemokines. Enhanced expression of ISG in microglia and microglial ISG chemokine response to TLR4 agonists were dependent on IFNAR1 and TLR4. To conclude, interferon triggered gene expression in microglia plays a major role in ischemia/reperfusion injury [24]. However, during ischemic stroke, activated microglia have been shown to play a dual role, and they secrete pro-inflammatory cytokines resulting in further damage [6] and also secrete anti-inflammatory factors [25, 26]. Three and 7 days after MCAO, edaravone, a free radical scavenger that mimics glutathione peroxidase (GPx), diminishes microglial activation and early accumulation of oxidative products in rats [27]. Similarly, multiple exposures to hyperbaric oxygen (HBO) reduced infarct volume by decreasing microglial activation [28]. Surprisingly, impaired microglial activation markedly increased infarct size and number of apoptotic neurons following ischemia (MCAO, 1 h followed by 24- or 72-h reperfusion periods) supporting the dual role of microglia [29]. Following ischemia, activated macrophages can be detected as soon as 2 h. Between 22–46 h, both blood born and resident macrophages are dispersed over the entire lesion and stay detectable for up to 1 week in mice following the 30-min ischemic insult [30]. Microglia found around the ischemic tissue migrate towards the ischemic lesion and remain in close association with neurons for a process called “capping” (following neuron death, capping helps in early recognition and quick phagocytic removal of dead neurons) [31, 32]. Genetic deficiency of lymphocyte function-associated antigen 1 (LFA-1) abolishes the ability of microglia to migrate towards injured neurons [33]. Also, microglia play a major role in the production of growth factor TGF-β1, which represents a neuroprotective property [34].